Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA EBITDA 2011-2026 | BPTS

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
-468 K -26.8 M -10.2 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
-55.6 M - 1.93 % $ 17.4 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
-12.5 M - -19.68 % $ 18.4 M canadaCanada
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
1.19 M $ 0.9 -2.33 % $ 6.62 M chinaChina
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
232 M $ 21.96 -0.68 % $ 3.64 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
-81.1 M $ 1.02 -0.49 % $ 428 M israelIsrael
Allakos Allakos
ALLK
-190 M - - $ 28.6 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
AlloVir AlloVir
ALVR
-46.1 M - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
122 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-124 M - - $ 10.1 M usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-87.1 M $ 6.4 4.4 % $ 63.3 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-64.5 M - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
-62.4 M - -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-29.5 M - 17.91 % $ 11.1 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.08 M - -52.27 % $ 4.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
172 M $ 21.41 1.9 % $ 1 B usaUSA
Aravive Aravive
ARAV
-70 M - -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
1.06 B - - $ 96.9 B britainBritain
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.3 M - -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-9.75 M - -2.5 % $ 5.88 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
-7.74 M $ 12.26 3.72 % $ 1.62 B australiaAustralia
AgeX Therapeutics AgeX Therapeutics
AGE
-23.9 M - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
15.3 B $ 105.46 -0.09 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
589 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-37.3 M - - $ 7.46 M israelIsrael
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-70.5 M $ 4.08 0.25 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-11.5 M $ 23.26 1.75 % $ 2.96 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-26.7 M - -3.03 % $ 260 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-262 M $ 1.44 -5.88 % $ 383 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
22 K - -45.71 % $ 1.2 M canadaCanada
BioXcel Therapeutics BioXcel Therapeutics
BTAI
-50.2 M $ 1.06 -3.64 % $ 12.9 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-41.4 M - - $ 35.4 M usaUSA
AVROBIO AVROBIO
AVRO
10.8 M - 1083.1 % $ 745 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-171 M $ 2.95 -3.28 % $ 296 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.93 M $ 2.91 -1.36 % $ 4.79 M israelIsrael
bluebird bio bluebird bio
BLUE
-216 M - - $ 546 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
-101 M - - $ 3.45 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA